CoChat

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

Open access
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., on behalf of the Simon Broome Familial Hyperlipidaemia Register Group · 2008 · European Heart Journal

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

AIMS: To examine the changes in coronary, all-cause, and cancer mortality in patients with heterozygous familial hypercholesterolaemia (FH) before and after lipid-lowering therapy with statins. METHODS AND RESULTS: A total of 3382 patients (1650 men) aged <80 years were recruited from 21 lipid clinics in the United Kingdom and followed prospectively between 1980 and 2006 for 46 580 person-years. There were 370 deaths, including 190 from coronary heart disease (CHD) and 90 from cancer. The standardized mortality ratio (compared with the population in England and Wales) was calculated before and from 1 January 1992. In patients aged 20-79 years, CHD mortality fell significantly by 37% (95% CI = 7-56) from 3.4- to 2.1-fold excess. Primary prevention resulted in a 48% reduction in CHD mortality from 2.0-fold excess to none, with a smaller reduction of nearly 25% in patients with established disease. Coronary mortality was reduced more in women than in men. In patients without known CHD at registration, all-cause mortality from 1992 was 33% (21-43), lower than in the general population, mainly due to a 37% (21-50) lower risk of fatal cancer. CONCLUSION: The results emphasize the importance of early identification of FH and treatment with statins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehn422

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 4

  1. 1969, 2, 1380
  2. 1999, Arteriosclerosis, Thrombosis, and Vascular Biology, 142, 105
  3. 1999, International Journal of Epidemiology, 15, 134
  4. Sawicka, 1976, Medline Rows With NULL issns Will Point To This, 24, 441

Cited by

See all 427

Metadata

Authors
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group
Affiliations
  • University of Oxford (GB)
  • The Royal Free Hospital (GB)
  • Shrewsbury and Telford Hospital NHS Trust (GB)
  • University Hospital of Wales (GB)
  • University of Manchester (GB)
  • University of London (GB)
Corresponding author
Neil, A.
Venue
European Heart Journal
Published
2008-05-20
Volume
29
Issue
21
Pages
2625-2633
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2123415255
Cited by
425
References
41
Citations by year
2026: 6 · 2025: 8 · 2024: 8 · 2023: 17 · 2022: 25 · 2021: 20 · 2020: 19 · 2019: 20 · 2018: 34 · 2017: 25 · 2016: 55 · 2015: 35 · 2014: 37 · 2013: 31 · 2012: 33
FWCI
17.57
Type
journal article
Language
en
Open access
Licence
other-oa
Locations
  • European Heart Journal (publishedVersion, other-oa)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Oxford University Research Archive (ORA) (University of Oxford) (acceptedVersion, cc-by-nc)
  • UCL Discovery (University College London) (submittedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Funders
  • Pfizer
  • British Heart Foundation (PG2005/014, RG/08/008/25291, RG3008)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
heterozygous familial hypercholesterolemia, statins, lipid-lowering therapy, coronary heart disease mortality, all-cause mortality, cancer mortality, primary prevention, sex differences, standardized mortality ratio
MeSH terms
Adult, Aged, Coronary Disease, England, Epidemiologic Methods, Female, Humans, Hyperlipoproteinemia Type II, Male, Middle Aged, Neoplasms, Registries, Wales, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. https://app.cochat.ai/papers/10.1093/eurheartj/ehn422
The paper
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group. (2008). Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. European Heart Journal. https://doi.org/10.1093/eurheartj/ehn422

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.